BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34496912)

  • 1. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population.
    Fan J; Luo S; Ye Y; Ju J; Zhang Z; Liu L; Yang J; Xia M
    Nutr Metab (Lond); 2021 Sep; 18(1):82. PubMed ID: 34496912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-specific prevalence and risk factors of metabolic-associated fatty liver disease among 75,570 individuals in eastern China.
    Chang M; Shao Z; Wei W; Shen P; Shen G
    Front Endocrinol (Lausanne); 2023; 14():1241169. PubMed ID: 37822594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults.
    Liu J; Wang G; Wu Y; Guan Y; Luo Z; Zhao G; Jiang Y
    Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population.
    Yang S; Cheng J; Zhang R; Sun H; Zhang H; Lyu S; Duan W
    Hepatol Res; 2022 Feb; 52(2):176-186. PubMed ID: 34751487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Observational and Cross-Sectional Study of the Prevalence of Breast Lesions and Metabolic Dysfunction-Associated Fatty Liver Disease and their Relationship in China.
    Li S; Xu Z; Li H; Tang J; Liang XY; Tian S; Wu J; Li X; Liu ZL; Xiao J; Chen YL; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    J Gastrointestin Liver Dis; 2022 Mar; 31(1):31-39. PubMed ID: 35306559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Is Associated with Cervical Stromal Involvement in Endometrial Cancer Patients: A Cross-Sectional Study in South China.
    Lin X; Chen C; Jiang T; Ma J; Huang L; Huang L; Lei H; Tong Y; Huang G; Mao X; Sun P
    Curr Oncol; 2023 Mar; 30(4):3787-3799. PubMed ID: 37185400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China.
    Li H; Guo M; An Z; Meng J; Jiang J; Song J; Wu W
    Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32168920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease.
    Seo JY; Bae JH; Kwak MS; Yang JI; Chung SJ; Yim JY; Lim SH; Chung GE
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study.
    Xie X; Guo B; Xiao X; Yin J; Wang Z; Jiang X; Li J; Long L; Zhou J; Zhang N; Zhang Y; Chen T; Kangzhuo B; Zhao X
    BMC Public Health; 2022 Jan; 22(1):118. PubMed ID: 35038997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China.
    Yuan Q; Wang H; Gao P; Chen W; Lv M; Bai S; Wu J
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in Northeastern Iran.
    Taheri E; Moslem A; Mousavi-Jarrahi A; Hatami B; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    Gastroenterol Hepatol Bed Bench; 2021; 14(Suppl1):S102-S111. PubMed ID: 35154609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study.
    Kemp W; Clayton-Chubb D; Majeed A; Glenister KM; Magliano DJ; Lubel J; Bourke L; Simmons D; Roberts SK
    J Gastroenterol Hepatol; 2022 Feb; 37(2):395-403. PubMed ID: 34693553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age at menarche and metabolic dysfunction-associated fatty liver disease: Evidence from a large population-based epidemiological study in Southwest China.
    Li K; Yin J; Qin Z; Ma B; He R; Zhuoma D; Wang Z; Liu Q; Zhao X
    Prev Med; 2023 Dec; 177():107776. PubMed ID: 37951543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of MAFLD in general population: A large cross-sectional study calls for concerted public health action.
    Prabhakar T; Prasad M; Kumar G; Kaushal K; Shenoy PS; Dubey S; Sarin SK
    Aliment Pharmacol Ther; 2024 Apr; 59(7):843-851. PubMed ID: 38321716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations.
    van Dijk AM; Dingerink S; Chilunga FP; Meeks KAC; Bahendeka S; Schulze MB; Danquah I; Osei TB; Serné E; Agyemang C; Holleboom AG
    J Clin Transl Hepatol; 2021 Aug; 9(4):494-502. PubMed ID: 34447678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperuricemia as an independent risk factor for metabolic dysfunction-associated fatty liver disease in nonobese patients without type 2 diabetes mellitus.
    Liu J; Wang C; Wang YT; Liu JX; Zhou TH; Yao SK; Chen G
    Am J Physiol Endocrinol Metab; 2023 Jul; 325(1):E62-E71. PubMed ID: 37285598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016.
    Zhang HJ; Wang YY; Chen C; Lu YL; Wang NJ
    Chin Med J (Engl); 2021 Jun; 134(13):1593-1601. PubMed ID: 34091530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.